Verastem Oncology To Present Long-Term Phase 2 RAMP 201 Data On AVMAPKI FAKZYNJA In Recurrent Low-Grade Serous Ovarian Cancer At SGO 2026
Benzinga Newsdesk 7 months ago
BiotechNewsGeneral
Plenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-grade serous ovarian cancer clinical trialVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to
Plenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-grade serous ovarian cancer clinical trial
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will present new long-term AVMAPKI™ FAKZYNJA™ combination therapy (avutometinib capsules; defactinib tablets) data from the Phase 2 RAMP 201 clinical trial at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women's Cancers. Additional abstracts accepted for presentation will also be shared at the meeting being held on April 10-13, 2026, in San Juan, Puerto Rico.